{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:59:49Z","timestamp":1789016389672,"version":"build-2803163510"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40744-023-00565-x","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T03:02:35Z","timestamp":1687143755000},"page":"809-823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison Between Early-Onset and Common Gout: A Systematic Literature Review"],"prefix":"10.1007","volume":"10","author":[{"given":"Anthony J.","family":"Amatucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4199-4844","authenticated-orcid":false,"given":"Lissa","family":"Padnick-Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7521-241X","authenticated-orcid":false,"given":"Brian","family":"LaMoreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Bulbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"565_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007\u20132016. Arthritis Rheumatol. 2019;71:991\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"565_CR2","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/art.41404","volume":"72","author":"S Safiri","year":"2020","unstructured":"Safiri S, Kolahi AA, Cross M, et al. Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990\u20132017: a systematic analysis of the global burden of disease study 2017. Arthritis Rheumatol. 2020;72:1916\u201327.","journal-title":"Arthritis Rheumatol"},{"key":"565_CR3","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11:649\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"565_CR4","doi-asserted-by":"crossref","unstructured":"Doherty M. New insights into the epidemiology of gout. Rheumatology. 2009; 48(2):2\u20138.","DOI":"10.1093\/rheumatology\/kep086"},{"key":"565_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"565_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76:29\u201342.","journal-title":"Ann Rheum Dis"},{"key":"565_CR7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford). 2007;46:1372\u20134.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11926-017-0688-y","volume":"19","author":"GE Thottam","year":"2017","unstructured":"Thottam GE, Krasnokutsky S, Pillinger MH. Gout and metabolic syndrome: a tangled web. Curr Rheumatol Rep. 2017;19:60.","journal-title":"Curr Rheumatol Rep"},{"key":"565_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","volume":"74","author":"P Richette","year":"2015","unstructured":"Richette P, Clerson P, Perissin L, Flipo RM, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015;74:142\u20137.","journal-title":"Ann Rheum Dis"},{"key":"565_CR10","doi-asserted-by":"crossref","unstructured":"Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med. 1998; 15:539\u201353.","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S"},{"key":"565_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/acr.20344","volume":"63","author":"PC Grayson","year":"2011","unstructured":"Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:102\u201310.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"565_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1681\/ASN.2005010063","volume":"16","author":"RJ Johnson","year":"2005","unstructured":"Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? J Am Soc Nephrol. 2005;16:1909\u201319.","journal-title":"J Am Soc Nephrol"},{"key":"565_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000157","volume":"3","author":"E Krishnan","year":"2014","unstructured":"Krishnan E. Interaction of inflammation, hyperuricemia, and the prevalence of hypertension among adults free of metabolic syndrome: NHANES 2009\u20132010. J Am Heart Assoc. 2014;3: e000157.","journal-title":"J Am Heart Assoc"},{"key":"565_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141749","volume":"10","author":"A Pan","year":"2015","unstructured":"Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional association between self-reported hypertension and gout: The Singapore Chinese Health Study. PLoS ONE. 2015;10: e0141749.","journal-title":"PLoS ONE"},{"key":"565_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ypmed.2015.10.003","volume":"81","author":"P Wandell","year":"2015","unstructured":"Wandell P, Carlsson AC, Ljunggren G. Gout and its comorbidities in the total population of Stockholm. Prev Med. 2015;81:387\u201391.","journal-title":"Prev Med"},{"key":"565_CR16","doi-asserted-by":"publisher","first-page":"25766","DOI":"10.1038\/srep25766","volume":"6","author":"A Pan","year":"2016","unstructured":"Pan A, Teng GG, Yuan JM, Koh WP. Bidirectional association between diabetes and gout: the Singapore Chinese Health Study. Sci Rep. 2016;6:25766.","journal-title":"Sci Rep"},{"key":"565_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/annrheumdis-2014-205827","volume":"75","author":"YH Rho","year":"2016","unstructured":"Rho YH, Lu N, Peloquin CE, et al. Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based BMI-matched cohort study. Ann Rheum Dis. 2016;75:91\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1219","key":"565_CR18","first-page":"e17","volume":"129","author":"YC Tung","year":"2016","unstructured":"Tung YC, Lee SS, Tsai WC, Lin GT, Chang HW, Tu HP. Association between gout and incident type 2 diabetes mellitus: a retrospective cohort study. Am J Med. 2016;129(1219):e17-25.","journal-title":"Am J Med"},{"issue":"679\u201387","key":"565_CR19","volume":"125","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008. Am J Med. 2012;125(679\u201387): e1.","journal-title":"Am J Med"},{"key":"565_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/acr.21791","volume":"65","author":"SP Juraschek","year":"2013","unstructured":"Juraschek SP, Miller ER 3rd, Gelber AC. Body mass index, obesity, and prevalent gout in the United States in 1988\u20131994 and 2007\u20132010. Arthritis Care Res (Hoboken). 2013;65:127\u201332.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"565_CR21","doi-asserted-by":"crossref","unstructured":"Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998; 8:250\u201361.","DOI":"10.1016\/S1047-2797(97)00204-4"},{"key":"565_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000712","volume":"4","author":"JA Singh","year":"2018","unstructured":"Singh JA, Cleveland JD. Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data. RMD Open. 2018;4: e000712.","journal-title":"RMD Open"},{"key":"565_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/rheumatology\/kes169","volume":"52","author":"CF Kuo","year":"2013","unstructured":"Kuo CF, Yu KH, See LC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford). 2013;52:111\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0134088","volume":"10","author":"SC Liu","year":"2015","unstructured":"Liu SC, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS ONE. 2015;10: e0134088.","journal-title":"PLoS ONE"},{"key":"565_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13075-017-1427-5","volume":"19","author":"JA Singh","year":"2017","unstructured":"Singh JA, Ramachandaran R, Yu S, et al. Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study. Arthritis Res Ther. 2017;19:228.","journal-title":"Arthritis Res Ther"},{"key":"565_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894\u2013900.","journal-title":"Circulation"},{"key":"565_CR27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2047487313514895","volume":"22","author":"LE Clarson","year":"2015","unstructured":"Clarson LE, Chandratre P, Hider SL, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22:335\u201343.","journal-title":"Eur J Prev Cardiol"},{"key":"565_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","volume":"49","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, See LC, Luo SF, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford). 2010;49:141\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3899\/jrheum.160596","volume":"44","author":"ZL Vincent","year":"2017","unstructured":"Vincent ZL, Gamble G, House M, et al. Predictors of mortality in people with recent-onset gout: a prospective observational study. J Rheumatol. 2017;44:368\u201373.","journal-title":"J Rheumatol"},{"key":"565_CR30","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s10067-019-04520-6","volume":"38","author":"IJM Disveld","year":"2019","unstructured":"Disveld IJM, Zoakman S, Jansen T, et al. Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and infectious diseases especially when having tophi and\/or high serum uric acid levels: a prospective cohort study. Clin Rheumatol. 2019;38:1385\u201391.","journal-title":"Clin Rheumatol"},{"key":"565_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1001\/jamacardio.2019.3201","volume":"4","author":"AS Klauser","year":"2019","unstructured":"Klauser AS, Halpern EJ, Strobl S, et al. Dual-energy computed tomography detection of cardiovascular monosodium urate deposits in patients with gout. JAMA Cardiol. 2019;4:1019\u201328.","journal-title":"JAMA Cardiol"},{"key":"565_CR32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4329\/wjr.v12.i8.184","volume":"12","author":"SH Barazani","year":"2020","unstructured":"Barazani SH, Chi WW, Pyzik R, et al. Quantification of uric acid in vasculature of patients with gout using dual-energy computed tomography. World J Radiol. 2020;12:184\u201394.","journal-title":"World J Radiol"},{"key":"565_CR33","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/RCT.0000000000001222","volume":"45","author":"GM Feuchtner","year":"2021","unstructured":"Feuchtner GM, Plank F, Beyer C, et al. Monosodium urate crystal deposition in coronary artery plaque by 128-slice dual-energy computed tomography: an ex vivo phantom and in vivo study. J Comput Assist Tomogr. 2021;45:856\u201362.","journal-title":"J Comput Assist Tomogr"},{"key":"565_CR34","first-page":"763","volume":"38","author":"M Gamala","year":"2020","unstructured":"Gamala M, Jacobs JWG, Linn-Rasker SP, et al. Cardiovascular risk in patients with new gout diagnosis: is monosodium urate volume at ankles and feet on dual-energy computed tomography associated with previous cardiovascular events? Clin Exp Rheumatol. 2020;38:763\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"565_CR35","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1093\/rheumatology\/keaa920","volume":"60","author":"A Marty-An\u00e9","year":"2021","unstructured":"Marty-An\u00e9 A, Norberciak L, Andr\u00e8s M, et al. Crystal deposition measured with dual-energy computed tomography: association with mortality and cardiovascular risks in gout. Rheumatology (Oxford). 2021;60:4855\u201360.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13075-018-1746-1","volume":"20","author":"M Roughley","year":"2018","unstructured":"Roughley M, Sultan AA, Clarson L, et al. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Arthritis Res Ther. 2018;20:243.","journal-title":"Arthritis Res Ther"},{"key":"565_CR37","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13075-015-0610-9","volume":"17","author":"MJ Roughley","year":"2015","unstructured":"Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015;17:90.","journal-title":"Arthritis Res Ther"},{"key":"565_CR38","doi-asserted-by":"crossref","unstructured":"Singh JA, Cleveland JD. Gout is associated with a higher risk of chronic renal disease in older adults: a retrospective cohort study of US Medicare population. BMC Nephrol. 2019; 20:93.","DOI":"10.1186\/s12882-019-1274-5"},{"key":"565_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031550","volume":"9","author":"AG Stack","year":"2019","unstructured":"Stack AG, Johnson ME, Blak B, et al. Gout and the risk of advanced chronic kidney disease in the UK health system: a national cohort study. BMJ Open. 2019;9: e031550.","journal-title":"BMJ Open"},{"key":"565_CR40","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar3806","volume":"14","author":"KH Yu","year":"2012","unstructured":"Yu KH, Kuo CF, Luo SF, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther. 2012;14:R83.","journal-title":"Arthritis Res Ther"},{"key":"565_CR41","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1681\/ASN.2020040523","volume":"31","author":"M Sellmayr","year":"2020","unstructured":"Sellmayr M, Hernandez Petzsche MR, Ma Q, et al. Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol. 2020;31:2773\u201392.","journal-title":"J Am Soc Nephrol"},{"key":"565_CR42","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.semarthrit.2012.09.009","volume":"42","author":"SP Juraschek","year":"2013","unstructured":"Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Association of kidney disease with prevalent gout in the United States in 1988\u20131994 and 2007\u20132010. Semin Arthritis Rheum. 2013;42:551\u201361.","journal-title":"Semin Arthritis Rheum"},{"key":"565_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/rheumatology\/kev418","volume":"55","author":"CF Kuo","year":"2016","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Impact of gout on the risk of atrial fibrillation. Rheumatology (Oxford). 2016;55:721\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR44","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","volume":"75","author":"CF Kuo","year":"2016","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Comorbidities in patients with gout prior to and following diagnosis: case-control study. Ann Rheum Dis. 2016;75:210\u20137.","journal-title":"Ann Rheum Dis"},{"key":"565_CR45","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/rheumatology\/ket265","volume":"52","author":"P Chandratre","year":"2013","unstructured":"Chandratre P, Roddy E, Clarson L, Richardson J, Hider SL, Mallen CD. Health-related quality of life in gout: a systematic review. Rheumatology (Oxford). 2013;52:2031\u201340.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/PROM.S8310","volume":"2010","author":"JD Hirsch","year":"2010","unstructured":"Hirsch JD, Terkeltaub R, Khanna D, et al. Gout disease-specific quality of life and the association with gout characteristics. Patient Relat Outcome Meas. 2010;2010:1\u20138.","journal-title":"Patient Relat Outcome Meas"},{"key":"565_CR47","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1093\/rheumatology\/keab804","volume":"61","author":"Z Jin","year":"2022","unstructured":"Jin Z, Feng X, Wang D, et al. Global, regional and national trends in sex- and age-specific disability-adjusted life years of musculoskeletal disorders, 1990\u20132019. Rheumatology (Oxford). 2022;61:2978\u201386.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR48","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"565_CR49","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/rheumatology\/kez685","volume":"59","author":"F Zaidi","year":"2020","unstructured":"Zaidi F, Narang RK, Phipps-Green A, et al. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus. Rheumatology (Oxford). 2020;59:2544\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13075-019-2007-7","volume":"21","author":"Y Toyoda","year":"2019","unstructured":"Toyoda Y, Pavelcov\u00e1 K, Klein M, et al. Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2. Arthritis Res Ther. 2019;21:219.","journal-title":"Arthritis Res Ther"},{"key":"565_CR51","doi-asserted-by":"crossref","unstructured":"Toyoda Y, Pavelcov\u00e1 K, Bohat\u00e1 J, et al. Identification of two dysfunctional variants in the ABCG2 urate transporter associated with pediatric-onset of familial hyperuricemia and early-onset gout. Int J Mol Sci. 2021; 22:2.","DOI":"10.3390\/ijms22041935"},{"key":"565_CR52","doi-asserted-by":"crossref","unstructured":"P\u00e1link\u00e1s M, Szab\u00f3 E, Kulin A, et al. Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia. Clin Exp Med. 2022 [Epub ahead of print].","DOI":"10.1007\/s10238-022-00848-7"},{"issue":"suppl 9","key":"565_CR53","first-page":"144","volume":"70","author":"C Collet","year":"2018","unstructured":"Collet C, Morel H, Ricquebourg M, et al. Identification of new and rare variants in ABCG2, SLC22A1 and ALDH16A1 genes in crystal-proven early-onset gout [abstract]. Arthritis Rheumatol. 2018;70(suppl 9):144.","journal-title":"Arthritis Rheumatol"},{"key":"565_CR54","first-page":"4321419","volume":"2020","author":"XF Huang","year":"2020","unstructured":"Huang XF, Sun L, Zhang C, et al. Whole-exome sequencing reveals a rare missense variant in SLC16A9 in a pedigree with early-onset gout. BioMed Res Int. 2020;2020:4321419.","journal-title":"BioMed Res Int"},{"issue":"suppl 2","key":"565_CR55","first-page":"373","volume":"76","author":"Q-H Li","year":"2017","unstructured":"Li Q-H, Chen L-X, Li Y-H, et al. More obesity and higher serum uric acid in early-onset gout patients in south China [abstract]. Ann Rheum Dis. 2017;76(suppl 2):373.","journal-title":"Ann Rheum Dis"},{"key":"565_CR56","doi-asserted-by":"crossref","unstructured":"Li QH, Zou YW, Lian SY, et a l. Sugar-sweeten beverage consumption Is associated with more obesity and higher serum uric acid in Chinese male gout patients with early onset. Front Nutr. 2022; 9:916811.","DOI":"10.3389\/fnut.2022.916811"},{"key":"565_CR57","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/acr2.11057","volume":"1","author":"Y Li","year":"2019","unstructured":"Li Y, Piranavan P, Sundaresan D, Yood R. Clinical characteristics of early-onset gout in outpatient setting. ACR Open Rheumatol. 2019;1:397\u2013402.","journal-title":"ACR Open Rheumatol"},{"key":"565_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2020.09.010","volume":"88","author":"Q Gao","year":"2021","unstructured":"Gao Q, Cheng X, Merriman TR, et al. Trends in the manifestations of 9754 gout patients in a Chinese clinical center: a 10-year observational study. Joint Bone Spine. 2021;88: 105078.","journal-title":"Joint Bone Spine"},{"key":"565_CR59","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1002\/acr.23706","volume":"71","author":"T Pascart","year":"2019","unstructured":"Pascart T, Norberciak L, Ea HK, Guggenbuhl P, Liot\u00e9 F. Patients with early-onset gout and development of earlier severe joint involvement and metabolic comorbid conditions: results from a cross-sectional epidemiologic survey. Arthritis Care Res (Hoboken). 2019;71:986\u201392.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"565_CR60","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/metabo11060399","volume":"11","author":"YS Suh","year":"2021","unstructured":"Suh YS, Noh HS, Kim HJ, et al. Differences in clinical and dietary characteristics, serum adipokine levels, and metabolomic profiles between early- and late-onset gout. Metabolites. 2021;11:399.","journal-title":"Metabolites"},{"issue":"suppl 2","key":"565_CR61","first-page":"142","volume":"77","author":"Q Li","year":"2018","unstructured":"Li Q, Zeng S-H, Du X-Y, et al. Fructose-containing beverages is an independent risk factor for gout early-onset in south China [abstract]. Ann Rheum Dis. 2018;77(suppl 2):142\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"suppl 2","key":"565_CR62","first-page":"1301","volume":"78","author":"J Herrou","year":"2019","unstructured":"Herrou J, Al Tabaa O, Gaix-Fontaine E, et al. Phenotype of patients with early-onset gout [abstract]. Ann Rheum Dis. 2019;78(suppl 2):1301.","journal-title":"Ann Rheum Dis"},{"issue":"suppl 9","key":"565_CR63","first-page":"xxx","volume":"73","author":"A Amatucci","year":"2021","unstructured":"Amatucci A, LaMoreaux B, Bulbin D. Early-onset gout (EOG) patients are an important and recalcitrant phenotype warranting further investigation: a systematic review [abstract]. Arthritis Rheumatol. 2021;73(suppl 9):xxx.","journal-title":"Arthritis Rheumatol"},{"key":"565_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14169","volume":"75","author":"WT Perng","year":"2021","unstructured":"Perng WT, Hung YM, Lai WY, Chu KA, Wang YH, Wei JC. Increased risk of glaucoma amongst new-onset gout patients aged 20\u201339 years: a nationwide population-based cohort study in Taiwan. Int J Clin Pract. 2021;75: e14169.","journal-title":"Int J Clin Pract"},{"key":"565_CR65","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005425","volume":"95","author":"B Zhang","year":"2016","unstructured":"Zhang B, Fang W, Zeng X, et al. Clinical characteristics of early- and late-onset gout: a cross-sectional observational study from a Chinese gout clinic. Medicine (Baltimore). 2016;95: e5425.","journal-title":"Medicine (Baltimore)"},{"key":"565_CR66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/annrheumdis-2014-205877","volume":"75","author":"AJ Phipps-Green","year":"2016","unstructured":"Phipps-Green AJ, Merriman ME, Topless R, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. Ann Rheum Dis. 2016;75:124\u201330.","journal-title":"Ann Rheum Dis"},{"key":"565_CR67","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/ar4348","volume":"15","author":"F Liot\u00e9","year":"2013","unstructured":"Liot\u00e9 F, Merriman T, Nasi S, So A. Workshop report: 4th European crystal network meeting. Arthritis Res Ther. 2013;15:304.","journal-title":"Arthritis Res Ther"},{"key":"565_CR68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, et al. Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol. 2017;69:203\u201312.","journal-title":"Arthritis Rheumatol"},{"key":"565_CR69","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin T, Keenan RT, Khanna PP, et al. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017;76:811\u201320.","journal-title":"Ann Rheum Dis"},{"key":"565_CR70","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6-month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56:2170\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"565_CR71","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol. 2017;69:1903\u201313.","journal-title":"Arthritis Rheumatol"},{"key":"565_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1161\/CIRCGENETICS.109.934455","volume":"3","author":"Q Yang","year":"2010","unstructured":"Yang Q, K\u00f6ttgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet. 2010;3:523\u201330.","journal-title":"Circ Cardiovasc Genet"},{"key":"565_CR73","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1038\/srep02014","volume":"3","author":"H Matsuo","year":"2013","unstructured":"Matsuo H, Ichida K, Takada T, et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep. 2013;3:2014.","journal-title":"Sci Rep"},{"key":"565_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000504","volume":"5","author":"M Kolz","year":"2009","unstructured":"Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5: e1000504.","journal-title":"PLoS Genet"},{"key":"565_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/hmg\/ddp489","volume":"19","author":"P van der Harst","year":"2010","unstructured":"van der Harst P, Bakker SJ, de Boer RA, et al. Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet. 2010;19:387\u201395.","journal-title":"Hum Mol Genet"},{"key":"565_CR76","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/gtmb.2021.0175","volume":"26","author":"Q Zheng","year":"2022","unstructured":"Zheng Q, Keliang W, Hongtao Q, Xiaosheng L. Genetic association between SLC22A12 variants and susceptibility to hyperuricemia: a meta-analysis. Genet Test Mol Biomarkers. 2022;26:81\u201395.","journal-title":"Genet Test Mol Biomarkers"},{"key":"565_CR77","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cbi.2012.12.018","volume":"202","author":"V Vasiliou","year":"2013","unstructured":"Vasiliou V, Sandoval M, Backos DS, et al. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1. Chem Biol Interact. 2013;202:22\u201331.","journal-title":"Chem Biol Interact"},{"key":"565_CR78","doi-asserted-by":"publisher","first-page":"e827","DOI":"10.1152\/ajpendo.00378.2020","volume":"319","author":"M Furuhashi","year":"2020","unstructured":"Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319:e827\u201334.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"565_CR79","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/tpj.2015.101","volume":"17","author":"RL Roberts","year":"2017","unstructured":"Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenom J. 2017;17:201\u20133.","journal-title":"Pharmacogenom J"},{"key":"565_CR80","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cpt.89","volume":"97","author":"CC Wen","year":"2015","unstructured":"Wen CC, Yee SW, Liang X, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015;97:518\u201325.","journal-title":"Clin Pharmacol Ther"},{"key":"565_CR81","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13075-020-02260-6","volume":"22","author":"M Toprover","year":"2020","unstructured":"Toprover M, Shah B, Oh C, et al. Initiating guideline-concordant gout treatment improves arterial endothelial function and reduces intercritical inflammation: a prospective observational study. Arthritis Res Ther. 2020;22:169.","journal-title":"Arthritis Res Ther"},{"issue":"suppl 9","key":"565_CR82","first-page":"22","volume":"74","author":"M Pillinger","year":"2022","unstructured":"Pillinger M, Obermeyer K, Padnick-Silver L, LaMoreaux B. Neutrophil-to-lymphocyte ratio among flaring and non-flaring uncontrolled gout patients undergoing pegloticase therapy as part of the phase 3 pivotal trials [abstract]. Arthritis Rheumatol. 2022;74(suppl 9):22.","journal-title":"Arthritis Rheumatol"},{"key":"565_CR83","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A. Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA. 2022;328:440\u201350.","journal-title":"JAMA"},{"key":"565_CR84","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-018-1612-1","volume":"20","author":"PL Evans","year":"2018","unstructured":"Evans PL, Prior JA, Belcher J, Mallen CD, Hay CA, Roddy E. Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies. Arthritis Res Ther. 2018;20:136.","journal-title":"Arthritis Res Ther"},{"key":"565_CR85","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00394-014-0766-0","volume":"53","author":"D Aune","year":"2014","unstructured":"Aune D, Norat T, Vatten LJ. Body mass index and the risk of gout: a systematic review and dose-response meta-analysis of prospective studies. Eur J Nutr. 2014;53:1591\u2013601.","journal-title":"Eur J Nutr"},{"key":"565_CR86","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/acr.20479","volume":"63","author":"MA DeMarco","year":"2011","unstructured":"DeMarco MA, Maynard JW, Huizinga MM, et al. Obesity and younger age at gout onset in a community-based cohort. Arthritis Care Res (Hoboken). 2011;63:1108\u201314.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"565_CR87","unstructured":"World Obesity Federation. Global Obesity Observatory: France. Available from: https:\/\/data.worldobesity.org\/country\/france-71\/#data_prevalence [Accessed 31 March 2023]."},{"key":"565_CR88","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clinthera.2016.12.011","volume":"39","author":"RT Keenan","year":"2017","unstructured":"Keenan RT. Limitations of the current standards of care for treating gout and crystal deposition in the primary care setting: a review. Clin Ther. 2017;39:430\u201341.","journal-title":"Clin Ther"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00565-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-023-00565-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-023-00565-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T14:44:18Z","timestamp":1688654658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-023-00565-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":88,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["565"],"URL":"https:\/\/doi.org\/10.1007\/s40744-023-00565-x","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"26 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}